18 : 1 lyso-PS | 89319-60-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: 18 : 1 lyso-PS
• 英文别名: 1-(9Z-octadecenoyl)-sn-glycero-3-phosphoserine；(2S)-2-amino-3-[hydroxy-[(2R)-2-hydroxy-3-[(Z)-octadec-9-enoyl]oxypropoxy]phosphoryl]oxypropanoic acid
• CAS: 89319-60-8
• 化学式: C₂₄H₄₆NO₉P
• 分子量: 523.604
• InChiKey: JZWNYZVVZXZRRH-YFKVPUFHSA-N

物化性质

• 沸点：
  673.2±65.0 °C(Predicted)
• 密度：
  1.156±0.06 g/cm3(Predicted)
• 碰撞截面：
  224.2 Ų [M+H]+ [CCS Type: DT, Method: single field calibrated with Agilent tune mix (Agilent)]

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  35
• 可旋转键数：
  25
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  166
• 氢给体数：
  4
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  18 : 1 lyso-PS 在 氨基-Α-环糊精 、 水 作用下， 以 aq. buffer 为溶剂， 反应 72.0h， 生成 油酸
  参考文献：
  名称：

  Lipase mimetic cyclodextrins

  摘要：

  脂肪酶类似物环糊精（CD）可以在生理条件下选择性水解天然的溶血磷脂酰甘油（GPLs）。

  DOI：

  10.1039/d0sc05711h
• 作为产物：
  描述：

  1,2-Dioleoyl-sn-glycero-3-phospho-L-serine (sodium) 、 三羟甲基氨基甲烷盐酸盐 、 氯化钾 、 、 盐酸 在 chloroform methanol 作用下， 以 水 为溶剂， 反应 20.0h， 以to give 1-oleoyl-sn-glycero-3-phospho-L-serine的产率得到18 : 1 lyso-PS
  参考文献：
  名称：

  IL-13 Production Inhibitor

  摘要：

  本发明提供了一种筛选IL-13产生抑制剂的筛选方法/筛选试剂盒，其包括使用(a)一种蛋白质，该蛋白质包括与由SEQ ID NO:1所代表的氨基酸序列相同或基本相同的氨基酸序列，或其部分肽段或其盐；和(b)能够特异性结合于该蛋白质的配体。通过该筛选获得的IL-13产生抑制剂等。本发明筛选所获得的IL-13产生抑制剂可用作呼吸系统疾病等的预防/治疗剂。

  公开号：

  US20090170116A1

文献信息

• Screening method
  申请人：Mori Masaaki

  公开号：US20050154190A1

  公开（公告）日：2005-07-14

  The present invention relates to a screening method/screening kit for screening a compound or its salt that changes the binding properties of (a) a protein containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 19, its partial peptides, or salts thereof, and (b) a ligand capable of binding specifically to the protein; compounds obtained by the screening or salts thereof; pharmaceuticals comprising the compounds or salts thereof; a protein containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 19; etc. The compounds obtained by the screening of the present invention are useful as agents for the prevention/treatment of, for example, neurodegenerative diseases, immunological diseases, edema, acid indigestion, etc.

  本发明涉及一种筛选方法/筛选试剂盒，用于筛选改变(a)与SEQ ID NO:1或SEQ ID NO:19所代表的氨基酸序列相同或基本相同的蛋白质、其部分肽段或其盐的结合性质，以及(b)能够特异性结合于蛋白质的配体的化合物或其盐。本发明筛选得到的化合物或其盐；包含该化合物或其盐的药物；与SEQ ID NO:19所代表的氨基酸序列相同或基本相同的蛋白质等均属于本发明的范畴。本发明所筛选得到的化合物可用作预防/治疗神经退行性疾病、免疫性疾病、水肿、酸性消化不良等的药剂。
• Method for screening compounds which change the binding properties of a protein with a ligand
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US07202040B2

  公开（公告）日：2007-04-10

  The present invention relates to a screening method/screening kit for screening a compound or its salt that changes the binding properties of (a) a protein containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 19, its partial peptides, or salts thereof, and (b) a ligand capable of binding specifically to the protein; compounds obtained by the screening or salts thereof; pharmaceuticals comprising the compounds or salts thereof; a protein containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 19; etc. The compounds obtained by the screening of the present invention are useful as agents for the prevention/treatment of, for example, neurodegenerative diseases, immunological diseases, edema, acid indigestion, etc.

  本发明涉及一种筛选方法/筛选试剂盒，用于筛选改变（a）蛋白质的结合特性，该蛋白质包含与由SEQ ID NO:1或SEQ ID NO:19所表示的氨基酸序列相同或基本相同的氨基酸序列、其部分肽段或其盐，以及（b）能够专门结合于该蛋白质的配体的化合物或其盐。此外，还包括通过筛选获得的化合物或其盐；包含该化合物或其盐的制药品；包含与由SEQ ID NO:19所表示的氨基酸序列相同或基本相同的氨基酸序列的蛋白质等。本发明筛选得到的化合物可用作预防/治疗神经退行性疾病、免疫性疾病、水肿、酸性消化不良等疾病的药物。
• IL-13 production inhibitor
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US07951548B2

  公开（公告）日：2011-05-31

  The present invention provides a screening method/screening kit for an IL-13 production inhibitor, which comprises using (a) a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or its partial peptide, or a salt thereof; and (b) a ligand capable of specifically binding to the protein; an IL-13 production inhibitor which is obtainable by said screening, and the like. The IL-13 production inhibitor which can be obtained by the screening of the present invention is useful as a prophylactic/therapeutic agent for, e.g., respiratory disease, etc.

  本发明提供了一种筛选IL-13产生抑制剂的筛选方法/筛选试剂盒，其包括使用(a)一种蛋白质，该蛋白质包括与SEQ ID NO: 1所代表的氨基酸序列相同或基本相同的氨基酸序列或其部分肽段或其盐;和(b)一种能够特异性结合于该蛋白质的配体；通过该筛选可获得的IL-13产生抑制剂等。本发明筛选获得的IL-13产生抑制剂可用作预防/治疗呼吸系统疾病等的药物。
• Gas-filled stabilized particles and methods of use
  申请人：Children's Medical Center Corporation

  公开号：US10577554B2

  公开（公告）日：2020-03-03

  Provided herein are various gas-filled particles having a stabilized membrane that encapsulates the gas. Pharmaceutical compositions, methods of use and treatment, and methods of preparation are also described.

  本文提供了各种充满气体的颗粒，这些颗粒具有封装气体的稳定膜。此外，还介绍了药物组合物、使用和处理方法以及制备方法。
• COMPOUND HAVING LYSOPHOSPHATIDYLSERINE RECEPTOR FUNCTION MODULATION ACTIVITY
  申请人：THE UNIVERSITY OF TOKYO

  公开号：US20150361119A1

  公开（公告）日：2015-12-17

  The object of the present invention is to provide a compound having a lysophosphatidylserine receptor function modulation activity or a salt thereof. A compound having a lysophosphatidylserine receptor function modulation activity or a salt thereof, or a pharmaceutical composition or a lysophosphatidylserine receptor function moderator containing such compound or salt is provided by the present invention.